Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crizanlizumab in Indian sickle cell disease patients with vaso-occlusive crises
NCT04662931Phase 4Completed
- Sponsor
- Novartis
- Start
- Jul 2021
- Primary completion
- Feb 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of crizanlizumab in sickle cell disease (SCD), sponsored by Novartis. Started Jul 2021; status: completed.
02
Drugs
crizanlizumab
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT04662931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04662931.